While ubiquitously multi-resistant bacteria are on the rise, peri-operative antimicrobial prophylaxis in trauma and near-to-bone surgical procedures has only been changed slightly during the last 25 years. Recent clinical studies concerning the bacterial spectrum and efficacy of antimicrobial treatment in infected trauma surgical patients are rare. The aim of the study was analysis of the contemporary bacterial spectrum and its antimicrobial resistance including the assessment of the appropriateness of peri-operative antimicrobial prophylaxis with cefuroxime.
Methods:
Patients of a level-I academic trauma center who underwent open or arthroscopic surgery because of a recent trauma necessitating the use of bone-near metal implants were included in the study. All patients in whom a surgical site infection (SSI) had developed during six weeks post-operatively necessitating surgical debridement and had positive microbiologic culture results from an intra-operative surgical site swab were analyzed, retrospectively. In particular, age, gender, date and duration of surgical interventions, and patient's related risk factors were collected, and infecting agents and their minimum inhibitory concentration values for 34 selected antimicrobial agents were evaluated. An SSI occurring later than 6 weeks post-operatively and patients with chronic and septic wounds were excluded. Statistical analysis was performed with SPSS® (IBM, Armonk, NY).
Results:
There were 438 pathogens cultured in specimens from 303 enrolled patients (female = 140, male = 163). The most frequent pathogens were Staphylococcus aureus (27.1%), S. epidermidis (20.6%), Enterococcus faecalis (13.6%), Escherichia coli (5.1%), and Pseudomonas aeruginosa (3.7%) accounting for 303 isolates. Of those, 89 (29.4%) were multi-resistant. Of the S. epidermidis isolates, 79.8% (n = 71) were resistant against Oxacillin and thus against most beta-lactam antibiotic agents. Altogether, only 44.1% of the infecting organisms were susceptible to cefuroxime, the antimicrobial agent most often being used for prophylactic purposes.
Conclusion:
Standardized antimicrobial prophylaxis with cephalosporins has to be reconsidered critically. Multi-resistant species such as S. epidermidis are an increasing challenge in trauma operations.
Get full access to this article
View all access options for this article.
References
1.
WeberDJ, RutalaWA. New antibiotic agents: Problems and prospects. Surg Infect, 2005; 6(Suppl 2):97–107.
2.
TurnerMC, MigalyJ. Surgical site infection: The clinical and economic impact. Clin Colon Rectal Surg, 2019; 32:157–165.
3.
HwabejireJO, KaafaraniHM, ImamAM, et al.Excessively long hospital stays after trauma are not related to the severity of illness: Let's aim to the right target!. JAMA Surg, 2013; 148:956–961.
4.
KirklandKB, BriggsJP, TrivetteSL, WilkinsonWE, SextonDJ. The impact of surgical-site infections in the 1990s: Attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol, 1999; 20:725–730.
5.
SchecklerWE. Hospital costs of nosocomial infections: A prospective three-month study in a community hospital. Infect Control, 1980; 1:150–152.
6.
WongES. The price of a surgical-site infection: More than just excess length of stay. Infect Control Hosp Epidemiol, 1999; 20:722–724.
7.
WhitehouseJD, FriedmanND, KirklandKB, et al.The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: Adverse quality of life, excess length of stay, and extra cost. Infect Control Hosp Epidemiol, 2002; 23:183–189.
8.
UrbanJA. Cost analysis of surgical site infections. Surg Infect, 2006; 7 (Suppl 1):S19–S22.
9.
EseonuKC, MiddletonSD, EseonuCC. A retrospective study of risk factors for poor outcomes in methicillin-resistant Staphylococcus aureus (MRSA) infection in surgical patients. J Orthop Surg Res, 2011; 6:25.
10.
CosgroveSE, CarmeliY. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis, 2003; 36:1433–1437.
11.
ListerJ. On the antiseptic principle in the practice of surgery. Brit Med J, 1867; 2:246–248.
12.
BurkeJF. Identification of the sources of staphylococci contaminating the surgical wound during operation. Ann Surg, 1963; 158:898–904.
NicholsRL, CondonRE, BariePS. Antibiotic prophylaxis in surgery—2005 and beyond. Surg Infect, 2005; 6:349–361.
15.
BergmanBR. Antibiotic prophylaxis in open and closed fractures: A controlled clinical trail. Acta Orthop Scand, 1982; 53:57–62.
16.
BoydRJ, BurkeJF, ColtonT. A double-blind clinical trial of prophylactiv antibiotics in hip fractures. J Bone Joint Surg Am, 1973; 55:1251–1258.
17.
BurnettJW, GustiloRB, WilliamsDN, KindAC. Prophylactic antibiotics in hip fractures. A double-blind, prospective study. J Bone Joint Surg Am, 1980; 62:457–462.
18.
DellingerEP, CaplanES, WeaverLD, et al.Duration of preventive antibiotic administration for open extremity fractures. Arch Surg, 1988; 123:333–339.
19.
EricsonC, LidgrenL, LindbergL. Cloxacillin in the prophylaxis of postoperative infections of the hip. J Bone Joint Surg Am, 1973; 55:808–813.
20.
FogelbergEV, ZitzmannEK, StichfieldFE. Prophylactic penicillin in orthopaedic surgery. J Bone Joint Surg Am, 1970; 52:95–98.
21.
FrongilloRF, DonatiL, FredericoG, et al.Clinical comparative study on the activity of cefamandole in the treatment of serious staphylococcal infections caused by methicillin-susceptible and methicillin-resistant strains. Antimicrob Agents Chemother, 1986; 29:789–796.
22.
GatellJM, GarciaS, LozanoML, et al.Perioperative cefamandole prophylaxis against infections. J Bone Joint Surg Am, 1987; 69:1189–1193.
23.
GatellJM, RibaJ, LozanoML, et al.Prophylactic cefamandole in orthopaedic surgery. J Bone Joint Surg Am, 1984; 66:1219–1222.
24.
GustiloRB. Use of antimicrobials in the management of open fractures. Arch Surg, 1979; 114:805–808.
25.
GustiloRB, AndersonJT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: Retrospective and prospective analyses. J Bone Joint Surg Am, 1976; 58:453–458.
26.
HoweCW. The problem of postoperative wound infections caused by Staphylococcus aureus. Ann Surg, 1957; 146:384–398.
27.
SchonholtzGJ, BorgiaCA, BlairJD. Wound sepsis in orthopaedic surgery. J Bone Joint Surg Am, 1962; 44-A:1548–1552.
28.
TengveB, KjellanderJ. Antibiotic prophylaxis in operations of trochanteric femoral fractures. J Bone Joint Surg Am, 1978; 60:97–99.
29.
BraunR, EnzlerMA, RittmannWW. A double-blind clinical trial of prophylactic cloxacillin in open fractures. J Orthop Trauma, 1987; 1:12–17.
30.
BoxmaH, BroekhuizenT, PatkaP, OostingH. Randomised controlled trial of single-dose antibiotic prophylaxis in surgical treatment of closed fractures: The Dutch Trauma Trial. Lancet, 1996; 347:1133–1137.
31.
Carsenti-EtesseH, DoyonF, DesplacesN, et al.Epidemiology of bacterial infection during management of open leg fractures. Eur J Clin Microbiol Infect Dis, 1999; 18:315–323.
32.
GarciaS, LozanoML, GatellJM, et al.Prophylaxis against Infection. Single-dose cefonicid compared with multiple-dose cefamandole. J Bone Joint Surg Am, 1991; 73:1044–1048.
33.
GuglielmoBJ, HohnDC, KooPJ, et al.Antibiotic prophylaxis in surgical procedures: A ciritcal analysis of the literature. Arch Surg, 1983; 118:943–955.
34.
GillespieWJ, WallenkampGH. Antibiotic prophylaxis for surgery for proximal femoral and other closed long bone fractures. Cochrane Database Syst Rev, 2010:CD000244.
35.
BucherBT, WarnerBW, DillonPA. Antibiotic prophylaxis and the prevention of surgical site infection. Curr Opin Pediatr, 2011; 23:334–338.
36.
SaveliCC, BelknapRW, MorganSJ, PriceCS. The role of prophylactic antibiotics in open fractures in an era of community-acquired methicillin-resistant Staphylococcus aureus. Orthopedics, 2011; 34:611–616.
37.
WarnockM, OgondaL, YewP, McIlvennyG. Antibiotic prophylaxis protocols and surgical site infection rates in trauma surgery: A prospective regional study of 26,849 procedures. Ulster Med J, 2019; 88:111–114.
38.
MaciejczakA, Wolan-NierodaA, WałaszekM, et al.Antibiotic prophylaxis in spine surgery: A comparison of single-dose and 72-hour protocols. J Hosp Infect, 2019; 103:202–310.
39.
StefaniS, VaraldoPE. Epidemiology of methicillin-resistant staphylococci in Europe. Clin Microbiol Infect, 2003; 9:1179–1186.
40.
KocianovaS, VuongC, YaoY, et al.Key role of poly-γ-DL-glutamic acid in immune evasion and virulence of Staphylococcus epidermidis. J Clin Invest, 2005; 115:688–694.
41.
BeckerK, BierbaumG, von EiffC, et al.Understanding the physiology and adaptation of staphylococci: A post-genomic approach. Int J Med Microbiol, 2007; 297:483–501.
TreviñoM, Martínez-LamasL, Romero-JungPA, et al.Endemic linezolid-resistant Staphylococcus epidermidis in a critical care unit. Eur J Clin Microbiol Infect Dis, 2009; 28:527–533.
44.
ChaJO, YooJI, YooJS, et al.Investigation of biofilm formation and its association with the molecular and clinical characteristics of methicillin-resistant Staphylococcus aureus. Osong Public Health Res Perspect, 2013; 4:225–132.
ZiebuhrW, HennigS, EckartM, et al.Nosocomial infections by Staphylococcus epidermidis: How a commensal bacterium turns into a pathogen. Int J Antimicrob Agents, 2006; 28(Suppl 1):S14–S20.
47.
LeeHY, ChenCL, LiuSY, et al.Impact of molecular epidemiology and reduced susceptibility to glycopeptides and daptomycin on outcomes of patients with methicillin-resistant Staphylococcus aureus bacteremia. PLoS One, 2015; 10:e0136171.
48.
PuetzlerJ, ZalavrasC, MoriartyTF, et al.Clinical practice in prevention of fracture-related infection: An international survey among 1197 orthopaedic trauma surgeons. Injury, 2019; 50:1208–1215.
49.
MujagicE, ZwimpferT, MartiWR, et al.Evaluating the optimal timing of surgical antimicrobial prophylaxis: Study protocol for a randomized controlled trial. Trials, 2014; 15:188.
50.
The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0 2015. www: eucast.org. (Last accessed January2, 2020).
51.
MitakeT, NishizukaT, TatebeM, HirataH. Adult distal humerus trauma with surgical intervention: CT analysis of fracture pattern, causes, and distribution. Nagoya J Med Sci, 2018; 80:199–205.
52.
WilliamsR, JupiterDC, MaassenNH. The incidence and risk factors of scaphoid fracture associated with radial head and neck fracture in trauma patients. J Am Acad Orthop Surg Glob Res Rev, 2019; 3:e055.
53.
FöhrweiserC. Korrelation der Schockraumversorgung polytraumatisierter Patienten am Universitätsklinikum Regensburg mit der aktuellen S3-Leitlinie Polytrauma / Schwerverletztenbehandlung; 2015.
54.
GowdAK, BohlDD, HamidKS, et al.Longer operative time is independently associated with surgical site infection and wound dehiscence following open reduction and internal fixation of the ankle. Foot Ankle Spec, 2019:1938640019835299.
55.
BertschiD, WeberWP, ZeindlerJ, et al.Antimicrobial prophylaxis redosing reduces surgical site infection risk in prolonged duration surgery irrespective of its timing. World J Surg, 2019; 43:2420–2425.
56.
AnsariS, HassanM, BarryHD, et al.Risk factors associated with surgical site infections: A retrospective report from a developing country. Cureus, 2019; 11:e4801.
57.
MoltonJS, TambyahPA, AngBS, et al.The global spread of healthcare-associated multidrug-resistant bacteria: A perspective from Asia. Clin Infect Dis, 2013; 56:1310–1318.
58.
DancerSJ. Controlling hospital-acquired infection: focus on the role of the environment and new technologies for decontamination. Clin Microbiol Rev, 2014; 27:665–690.
59.
Ostholm-BalkhedA, TärnbergM, NilssonM, et al.Travel-associated faecal colonization with ESBL-producing Enterobacteriaceae: Incidence and risk factors. J Antimicrob Chemother, 2013; 68:2144–2153.
60.
KuenzliE, JaegerVK, FreiR, et al.High colonization rates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in Swiss travellers to South Asia—a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors. BMC Infect Dis, 2014; 14:528.
61.
SoléM, PitartC, OliveiraI, et al.Extended spectrum β-lactamase-producing Escherichia coli faecal carriage in Spanish travellers returning from tropical and subtropical countries. Clin Microbiol Infect, 2014; 20:O636–O639.
62.
von WintersdorffCJ, PendersJ, StobberinghEE, et al.High rates of antimicrobial drug resistance gene acquisition after international travel, The Netherlands. Emerg Infect Dis, 2014; 20:649–657.
63.
LübbertC, StraubeL, SteinC, et al.Colonization with extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacteriaceae in international travelers returning to Germany. Int J Med Microbiol, 2015; 305:148–156.
64.
MacFaddenDR, BogochII, BrownsteinJS, et al.A passage from India: Association between air traffic and reported cases of New Delhi Metallo-beta-lactamase 1 from 2007 to 2012. Travel Med Infect Dis, 2015; 13:295–299.
65.
OlaitanAO, DiaNM, GautretP, et al.Acquisition of extended-spectrum cephalosporin- and colistin-resistant Salmonella enterica subsp. enterica serotype Newport by pilgrims during Hajj. Int J Antimicrob Agents, 2015; 45:600–604.
66.
MansouriS, ShareifiS. Antimicrobial resistance pattern of Escherichia coli causing urinary tract infections, and that of human fecal flora, in the southeast of Iran. Microb Drug Resist, 2002; 8:123–128.
67.
SandiumengeA, DiazE, BodíM, RelloJ. Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of “The Tarragona Strategy”. Intensive Care Med, 2003; 29:876–883.
68.
JacksonJ, ChenC, BuisingK. Aminoglycosides: How should we use them in the 21st century?. Curr Opin Infect Dis, 2013; 26:516–525.
69.
Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut (RKI). Hygienemaßnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen Stäbchen. Empfehlung der Kommission für Kranken-haushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut (RKI). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2012; 55:1311–1354.
70.
EmoriTG, GaynesRP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Micro Rev, 1993; 6:428–442.
71.
MarsikFJ, ParisiJT. Significance of Staphylococcus epidermidis in the clinical laboratory. Appl Microbiol, 1973; 25:11–14.
72.
MalicS, HillKE, PlayleR, et al.In vitro interaction of chronic wound bacteria in biofilms. J Wound Care, 2011; 20:569.
73.
NamvarAE, BastarahangS, AbbasiN, et al.Clinical characteristics of Staphylococcus epidermidis: A systematic review. GMS Hyg Infect Control, 2014; 9:Doc23.
74.
CostertonJW, LewandowskiZ, CaldwellDE, et al.Microbial biofilms. Annu Rev Microbiol, 1995; 49:711–745.
75.
Jean-BaptisteE, BlanchemainN, NeutC, et al.Evaluation of the anti-infectious properties of polyester vascular prostheses functionalised with cyclodextrin. J Infect, 2014; 68:116–124.
76.
SchoenfelderSM, LangeC, EckartM, et al.Success through diversity - how Staphylococcus epidermidis establishes as a nosocomial pathogen. Int J Med Microbiol, 2010; 300:380–386.
77.
HuyckeMM, SahmDF, GilmoreMS. Multiple-drug resistant enterococci: The nature of the problem and an agenda for the future. Emerg Infect Dis, 1998; 4:239–249.
78.
BenesJ, DzupovaO, SetinaM, et al.Relapsing endocarditis caused by Enterococcus faecalis forming small colony variants. Scand J Infect Dis, 2013; 45:800–803.
79.
WellinghausenN, ChatterjeeI, BergerA, et al.Characterization of clinical Enterococcus faecalis small-colony variants. J Clin Microbiol, 2009; 47:2802–2811.
80.
O'DriscollT, CrankCW. Vancomycin-resistant enterococcal infections: Epidemiology, clinical manifestations, and optimal management. Infect Drug Resist, 2015; 8:217–230.
81.
SasaharaT, HayashiS, HosodaK, et al.Comparison of hand hygiene procedures for removing Bacillus cereus spores. Biocontrol Sci, 2014; 19:129–134.
82.
Ruppé É, WoertherPL, BarbierF. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care, 2015; 5:61.
83.
PastarI, NusbaumAG, GilJ, et al.Interactions of methicillin resistant Staphylococcus aureus USA300 and Pseudomonas aeruginosa in polymicrobial wound infection. PLoS One, 2013; 8:e56846.
84.
WolskaKI, GrudniakAM, RudnickaZ, MarkowskaK. Genetic control of bacterial biofilms. J Appl Genet, 2016; 57:225–238.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
